Chronic Myelogenous Leukemia

STI571 reduces proliferative advantage of malignant progenitor cells

Published in Blood Weekly, July 18th, 2002

by Michael Greer, senior medical writer - Researchers in the United States have shed new light on the mechanisms of a powerful and novel treatment for leukemia.

"Imatinib mesylate (STI571) is a promising new treatment for chronic myelogenous leukemia (CML)," according to Dr. Melissa S. Holtz and colleagues at the City of Hope National Medical Center in Duarte, California, and the University of California at Los Angeles.

Although this agent does not trigger the death of CML progenitor cells, it removes the competitive advantage they have over healthy stem cells, Holtz and coauthors found.

Proliferation of progenitor cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry